JP2016521754A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521754A5
JP2016521754A5 JP2016519675A JP2016519675A JP2016521754A5 JP 2016521754 A5 JP2016521754 A5 JP 2016521754A5 JP 2016519675 A JP2016519675 A JP 2016519675A JP 2016519675 A JP2016519675 A JP 2016519675A JP 2016521754 A5 JP2016521754 A5 JP 2016521754A5
Authority
JP
Japan
Prior art keywords
administration
difficile
use according
days
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016519675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521754A (ja
JP6691477B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/042298 external-priority patent/WO2014201346A1/en
Publication of JP2016521754A publication Critical patent/JP2016521754A/ja
Publication of JP2016521754A5 publication Critical patent/JP2016521754A5/ja
Application granted granted Critical
Publication of JP6691477B2 publication Critical patent/JP6691477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016519675A 2013-06-14 2014-06-13 クロストリジウム・ディフィシル(c.difficile)に対して免疫する組成物及び方法 Active JP6691477B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
US61/835,246 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (3)

Publication Number Publication Date
JP2016521754A JP2016521754A (ja) 2016-07-25
JP2016521754A5 true JP2016521754A5 (https=) 2017-07-27
JP6691477B2 JP6691477B2 (ja) 2020-04-28

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519675A Active JP6691477B2 (ja) 2013-06-14 2014-06-13 クロストリジウム・ディフィシル(c.difficile)に対して免疫する組成物及び方法

Country Status (12)

Country Link
US (4) US9730994B2 (https=)
EP (1) EP3007724B1 (https=)
JP (1) JP6691477B2 (https=)
KR (1) KR20160020543A (https=)
CN (1) CN105611942A (https=)
AU (1) AU2014277981B2 (https=)
BR (1) BR112015031088A2 (https=)
CA (1) CA2915279A1 (https=)
MX (1) MX2015017257A (https=)
SG (1) SG11201510166YA (https=)
TW (1) TWI648063B (https=)
WO (1) WO2014201346A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル(c.difficile)に対して免疫する組成物及び方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102625114B1 (ko) * 2017-09-28 2024-01-12 화이자 인코포레이티드 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
EP2970400A1 (en) * 2013-03-15 2016-01-20 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
KR20150133770A (ko) 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル(c.difficile)に対して免疫する組成物及び方法

Similar Documents

Publication Publication Date Title
JP2016521754A5 (https=)
JP2015057451A5 (https=)
JP2016540785A5 (https=)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2016540021A5 (https=)
JP2018531984A5 (https=)
JP2013536240A5 (https=)
JP2012506411A5 (https=)
JP2014523878A5 (https=)
JP2013067645A5 (https=)
JP2012193216A5 (https=)
JP2015520196A5 (https=)
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
HK1218865A1 (zh) 用於降低多发性硬化症中丘脑损伤的拉喹莫德
JP2012021028A5 (https=)
JP2016530291A5 (https=)
WO2021205225A8 (en) 25-hydroxyvitamin d for the treatment of sars-cov-2 infection
JP2014507475A5 (https=)
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
JP2016505050A5 (https=)
JP2016512247A5 (https=)
CN104337916A (zh) 一种手脚冰凉及脚气的中药药剂
JP2017061488A5 (https=)